MindRank AI

MindRank AI is a pioneering startup that operates at the intersection of artificial intelligence (AI), biology, and chemistry to revolutionize drug discovery. The company's primary focus is to expedite the process of drug discovery by leveraging machine learning and AI technologies. Their clientele primarily consists of biopharma companies, with whom they collaborate to develop AI-enabled drug discovery solutions, particularly for hard-to-drug molecular targets.

MindRank's business model is centered around the development of proprietary drugs and the provision of AI-enabled drug discovery services. Their proprietary drug, MDR-001, a GLP-1 RA designed to treat obesity and type 2 diabetes mellitus, received US IND approval in just 19 months. The company also successfully delivered an allosteric inhibitor with Best-in-Class potential to a publicly traded biotech company.

The company generates revenue through the sale of its proprietary drugs and the provision of AI-enabled drug discovery services to biopharma companies. MindRank's team of over 40 scientists, including top biopharma experts and global AI competition winners, brings a wealth of industry experience and success in drug discovery and AI-driven technological innovations.

MindRank has been recognized for its innovative work, being named one of Forbes Asia's "100 to Watch" in 2023. It has also secured funding from the Dynamic Resilience program and had its proprietary AI solution nominated as one of the "Top AI Breakthroughs in Biopharma from 2018 to 2020" by Deep Pharma Intelligence.

Keywords: Artificial Intelligence, Drug Discovery, Biopharma, Machine Learning, Proprietary Drugs, GLP-1 RA, Allosteric Inhibitor, Obesity, Type 2 Diabetes Mellitus, Forbes Asia's "100 to Watch".